Abstract: This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with Mycobacterium tuberculosis (Mtb) that is resistant to multiple antibiotic agents.

Abstract: Provided herein is a delivery system, including: (a) an optical sensor configured to detect data to create a map of a patient bodily surface; and (b) a dispenser operatively associated with the optical sensor and configured to deliver compositions (optionally including cells) to the patient bodily surface based upon the data or map. Methods of forming a tissue on a patient bodily surface of a patient in need thereof are also provided, as are methods, systems and computer program products useful for processing patient bodily surface data.

Abstract: The present disclosure relates to a phosphorus compound represented by the following Chemical Formula 1. In the above Chemical Formula 1, Ar is aryl and R1, R2, R3, R4, R5, and R6 are each independently H, substitutable linear or branched C1-C20 alkyl and substitutable C6-C20 aryl, the aryl includes a member selected from the group consisting of phenyl, biphenyl, naphthalene, fluorene, anthracene, phenanthrene, pyrene, fluoranthen, chrysene, benzofluoranthen, perylene, quinoline, indenoanthracene, indenophenanthrene, hydroanthracene, dibenzothiophen, dibenzofuran, and combinations thereof, and the substitution is substitution with C1-C6 alkyl or C6-C20 aryl, but may not be limited thereto.

Abstract: The present invention includes two embodiments of a tethered ankle-foot prosthesis, one with a single toe to provide plantarflexion and with two independently-actuated toes that are coordinated to provide plantarflexion and inversion-eversion torques. An end-effector was designed which is worn by a subject, and which was integrated with existing off-board motor and control hardware, to facilitate high bandwidth torque control. The platform is suitable for haptic rendering of virtual devices in experiments with humans, which may reveal strategies for improving balance or allow controlled comparisons of conventional prosthesis features. A similar morphology is also effective for autonomous devices.

Abstract: The present invention discloses CrN thermoelectric material and its preparation method, which belongs to the field of thermoelectric materials. Here, we provide a study for thermoelectric properties, hardness, wear-resisting performance and thermal stability of CrN. These results show that CrN possesses excellent mechanical properties and thermal stability. The hardness of the bulk CrN sample is as high as 735.76 HV, which is far superior to most of thermoelectric materials. The thermogravimetric analysis test indicates that CrN remain stable at 873 K. Friction and wear test results demonstrate that the low friction coefficient (˜0.42) and good wear resistance of CrN. The maximum ZT value of 0.104 is observed at 848 K. In this way, CrN may be a promising thermoelectric material in extreme environment application which requires both mechanical and thermoelectric properties. Such as collision avoidance systems and outerspace.

Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of FSHR. The invention provides novel peptides that specifically bind to Follicle-stimulation hormone receptor (FSHR).

Abstract: NNA-derived specific adducts represent an integrated biomarker of exposure to thirdhand smoke (THS) as NNA is unique to THS. The NNA-dG covalent binding adduct could serve as such a biomarker, and play a role in identifying individuals exposed to THS, thus providing critical information for early detection and prevention.

Abstract: Disclosed is an AMS process using a water-leachable alloy that reacts with water and dissolves, and a porous metal manufactured using the same. An AMS precursor including element groups that are selected in consideration of the relationship of heat of mixing with the water-leachable alloy composition to be subjected to the AMS process is immersed in the alloy melt, thus manufacturing a bi-continuous structure alloy. The bi-continuous structure alloy is subjected to dealloying using water, thus manufacturing the porous metal. The water-leachable alloy is a Ca-based alloy having high reactivity to water and high oxidation resistance at high temperatures, and a dealloying process thereof is performed using only pure water, unlike a conventional dealloying process performed using a toxic etching solution of a strong acid/strong base. The metal porous body has high elongation, a large surface area, and low thermal conductivity.

Abstract: The present disclosure provides opsins, including variant opsins with increased activity and/or increased trafficking to the plasma membrane. The opsins are useful in therapeutic and screening applications, which are also provided.

Abstract: A universal remote control (URC) is programmed to control a particular type and make of electronic consumer device using a graphical user interface. A plurality of images is displayed on the user-interface. Each image of the plurality of images is a digital photograph of an electronic consumer device or a remote control device usable to control the corresponding electronic consumer device. A user selects the digital photograph of the particular type and make of electronic consumer device or its corresponding remote control device. Codeset information associated with the selected device is transmitted to the URC such that the URC is programmed to control the selected device. If the codeset information is a codeset identifier, then it is displayed on the user interface. The user enters the codeset identifier into the URC such that the URC is programmed to control the selected device.

Abstract: Autonomic cooling of a substrate is achieved using a porous thermal protective layer to provide evaporative cooling combined with capillary pumping. The porous thermal protective layer is manufactured onto the substrate. A vascular network is integrated between the substrate and the protective layer. Applied heat causes fluid contained in the protective layer to evaporate, removing heat. The fluid lost to evaporation is replaced by capillary pressure, pulling fluid from a fluid-containing reservoir through the vascular network. Cooling occurs as liquid evaporates from the protective layer.

Abstract: Disclosed herein are ceramic selective membranes and methods of forming the ceramic selective membranes by forming a selective silica ceramic on a porous membrane substrate. Representative ceramic selective membranes include ion-conductive membranes (e.g., proton-conducting membranes) and gas selective membranes. Representative uses for the membranes include incorporation into fuel cells and redox flow batteries (RFB) as ion-conducting membranes.

Abstract: This disclosure relates to libraries of oligosaccharides comprising multiple individual oligosaccharides derived from cells that contain a tag or detectable marker. In certain embodiments, the tag or detectable marker is an oxygen linked to the oligosaccharides through the first carbon of a sugar ring. In certain embodiments, the disclosure relates to methods of generating the libraries of oligosaccharides using saccharides, e.g., monosaccharides, or a disaccharide, in which hydroxyl groups are chemically acetylated.

Abstract: A method for analysis of hydrocarbons in water, the method comprising the steps of: extracting the hydrocarbons from a water sample; introducing the extracted hydrocarbons to a solvent system; determining the relative concentrations of the hydrocarbons in the solvent system and at least one solvent in the solvent system by 1H NMR analysis, wherein the solvent system comprises at least one solvent with a 1H NMR signal distinguishable from a 1H NMR signal of the hydrocarbons.

Abstract: Functional electrical stimulation (FES) cycling devices and associated methods are generally described. An FES cycling device may comprise a crank, two or more pedals connected to the crank, one or more sensors adapted to measure position and/or velocity of the crank, and one or more electrodes configured to deliver electrical stimulation to a person associated with the cycling device. In some cases, the FES cycling device further comprises a controller configured to receive input signals from the one or more sensors and deliver output signals to the one or more electrodes. In certain cases, the controller may dynamically generate a control signal to deliver an amount of electrical stimulation to a muscle group (e.g., quadriceps femoris, gluteal muscles, hamstring muscles) based on the value of a determined torque transfer ratio between a joint of the person and the crank of the cycling device. The electrical stimulation may, in some cases, cause the person to pedal the cycling device.

Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Abstract: There is provided an integrated-optic transmitter for transmitting light pulses to a further optical apparatus for generating a quantum cryptographic key according to at least one quantum cryptography technique. There is also provided an integrated-optic receiver for generating a quantum cryptographic key from light pulses received from a further optical apparatus. The transmitter apparatus splits incoming light into two paths to temporally separate the split light pulses and controls the output intensity of each split pulse as well as the phase of at least one of the split pulses. The receiver apparatus receives first and second light pulses and controls the output intensity of each said pulse between a first and a second optical detector. The light input into the second detector passes through an integrated element that controls the amount of light output into two paths that recombine before at least a portion is output to the second detector.

Abstract: Medical treatment simulation systems and devices are disclosed. One device includes an overlay, a simulated treatment structure, at least one feedback device, and at least one processor. The overlay is configured to be secured to the live subject and to cover at least a portion of a body of the live subject. The simulated treatment structure is configured to simulate a structure associated with the medical procedure. The at least one feedback device is configured to provide a feedback signal to the live subject. The at least one processor is connected to the simulated treatment structure and the at least one feedback device. The processor is programmed to operate the feedback device to provide the feedback signal based upon input generated from interaction between a treatment provider and the simulated treatment structure. The disclosed devices may be used to simulate intravenous, catheter, defibrillation, and/or thoracic treatments.

Abstract: Various examples related to electromagnetic interference (EMI) energy mitigation techniques are provided. In one example, a method includes adjusting switching angles of a switching circuit based on resolution bandwidths (RBWs) associated with an EMI frequency spectrum of the switching circuit and weight coefficients of the RBWs. The total energy of the switching circuit can be reduced by adjusting an average duty cycle of the switching circuit. EMI spectrum information can be determined based upon switching angles of a switching circuit. For example, weighted errors corresponding to differences between reference harmonic magnitudes and determined harmonic magnitudes can be determined. In response to a comparison of a maximum weighted error to a preset tolerance threshold, adjustment to the switching angles can be determined and/or applied.

Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine or cystamine compositions. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).